{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cui H"],"funding":["Deutsche Forschungsgemeinschaft","Deutsche Krebshilfe","National Natural Science Foundation of China"],"pagination":["e2300591"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11469062"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(24)"],"pubmed_abstract":["To address the challenge of drug resistance and limited treatment options for recurrent gliomas with IDH1 mutations, a highly miniaturized screening of 2208 FDA-approved drugs is conducted using a high-throughput droplet microarray (DMA) platform. Two patient-derived temozolomide-resistant tumorspheres harboring endogenous IDH1 mutations (IDH1<sup>mut</sup> ) are utilized. Screening identifies over 20 drugs, including verteporfin (VP), that significantly affected tumorsphere formation and viability. Proteomics analysis reveals that nuclear pore complex may be a potential VP target, suggesting a new mechanism of action independent of its known effects on YAP1. Knockdown experiments exclude YAP1 as a drug target in tumorspheres. Pathway analysis shows that NUP107 is a potential upstream regu"],"journal":["Advanced healthcare materials"],"pubmed_title":["Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip."],"pmcid":["PMC11469062"],"funding_grant_id":["Project‐ID404521405,SFB1389–UNITEGlioblastoma,WorkpackageA04","32201098","70114934","70111964"],"pubmed_authors":["Schilling M","Popova AA","Herold-Mende C","Reischl M","Turcan S","Cui H","Levkin PA","Sun X"],"additional_accession":[]},"is_claimable":false,"name":"Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.","description":"To address the challenge of drug resistance and limited treatment options for recurrent gliomas with IDH1 mutations, a highly miniaturized screening of 2208 FDA-approved drugs is conducted using a high-throughput droplet microarray (DMA) platform. Two patient-derived temozolomide-resistant tumorspheres harboring endogenous IDH1 mutations (IDH1<sup>mut</sup> ) are utilized. Screening identifies over 20 drugs, including verteporfin (VP), that significantly affected tumorsphere formation and viability. Proteomics analysis reveals that nuclear pore complex may be a potential VP target, suggesting a new mechanism of action independent of its known effects on YAP1. Knockdown experiments exclude YAP1 as a drug target in tumorspheres. Pathway analysis shows that NUP107 is a potential upstream regu","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2026-06-07T07:38:00.154Z","creation":"2025-04-04T13:55:07.761Z"},"accession":"S-EPMC11469062","cross_references":{"pubmed":["37162029"],"doi":["10.1002/adhm.202300591"]}}